Rallybio Faces Nasdaq Delisting Warning
Ticker: RLYB · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1739410
| Field | Detail |
|---|---|
| Company | Rallybio Corp (RLYB) |
| Form Type | 8-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, nasdaq, compliance
Related Tickers: RLYB
TL;DR
Nasdaq sent Rallybio a delisting warning, stock might get booted.
AI Summary
Rallybio Corporation announced on February 24, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet a continued listing rule. The company is currently evaluating the notice and plans to respond to Nasdaq.
Why It Matters
This notice suggests potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A delisting warning from a major exchange like Nasdaq poses a significant risk to the company's market presence and investor accessibility.
Key Players & Entities
- Rallybio Corporation (company) — The company filing the 8-K
- Nasdaq Stock Market (company) — The exchange that issued the notice
FAQ
What specific listing rule did Rallybio Corporation fail to meet?
The filing does not specify the exact listing rule that Rallybio Corporation failed to meet, only that it received a notice of failure to satisfy a continued listing rule.
When did Rallybio Corporation receive the notice from Nasdaq?
Rallybio Corporation received the notice on February 24, 2025.
What is Rallybio Corporation's plan in response to the notice?
Rallybio Corporation is currently evaluating the notice and intends to respond to Nasdaq.
What is the potential consequence of failing to meet Nasdaq's listing requirements?
The potential consequence is delisting from the Nasdaq Stock Market.
Where is Rallybio Corporation's principal executive office located?
Rallybio Corporation's principal executive offices are located at 234 Church Street, Suite 1020, New Haven, Connecticut 06510.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding Rallybio Corp (RLYB).